Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CNTX 
Context Therapeutics Inc (CNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CNTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.2
1 Year Target Price $5.2
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.44% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.05M USD | Price to earnings Ratio - | 1Y Target Price 5.2 |
Price to earnings Ratio - | 1Y Target Price 5.2 | ||
Volume (30-day avg) 5 | Beta 1.91 | 52 Weeks Range 0.49 - 2.59 | Updated Date 09/17/2025 |
52 Weeks Range 0.49 - 2.59 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.22% | Return on Equity (TTM) -37.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -10527864 | Price to Sales(TTM) - |
Enterprise Value -10527864 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.6 | Shares Outstanding 89704200 | Shares Floating 37696393 |
Shares Outstanding 89704200 | Shares Floating 37696393 | ||
Percent Insiders 2.33 | Percent Institutions 76.78 |
Upturn AI SWOT
Context Therapeutics Inc
Company Overview
History and Background
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for hormone-driven cancers. Founded in 2015, it aims to address unmet needs in breast, ovarian, and endometrial cancers.
Core Business Areas
- Onapristone Extended Release (ONA-XR): ONA-XR is the company's lead product candidate, an investigational progesterone receptor (PR) antagonist for the treatment of hormone-driven cancers.
- CTX-472: CTX-472 is a clinical stage anti-claudin 6 antibody-drug conjugate for claudin 6 expressing tumors. Currently in phase 1 clinical trials.
Leadership and Structure
Martin Lehr is the CEO. The company has a board of directors and a management team focused on research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Onapristone Extended Release (ONA-XR): ONA-XR, an investigational progesterone receptor (PR) antagonist. It is in clinical trials for progesterone receptor positive cancers. There is no current market share as this is still in clinical trials. Competitors include standard of care treatments like chemotherapy and hormone therapies, and companies developing novel therapies for these cancers.
- CTX-472: CTX-472 is a clinical stage anti-claudin 6 antibody-drug conjugate for claudin 6 expressing tumors. Currently in phase 1 clinical trials. There is no current market share as this is still in clinical trials. Competitors include other companies developing ADCs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. There is a growing demand for personalized medicine and targeted therapies for cancer.
Positioning
Context Therapeutics is positioned as a company focused on hormone-driven cancers with a lead candidate targeting the progesterone receptor. Its competitive advantage lies in its specific focus and potentially novel mechanism of action.
Total Addressable Market (TAM)
The total addressable market for breast, ovarian, and endometrial cancers is substantial, estimated to be in the billions of dollars. Context Therapeutics' positioning within this TAM depends on the success of its clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Focused on hormone-driven cancers
- Novel progesterone receptor antagonist (ONA-XR)
- Experienced management team
- Anti-claudin 6 antibody-drug conjugate
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently marketed products
- Reliance on external funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approval of ONA-XR
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- SNY
- MRK
- PFE
Competitive Landscape
Context Therapeutics faces significant competition from established pharmaceutical companies with broader portfolios and greater resources. Its success depends on demonstrating superior efficacy and safety compared to existing therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily in research and development activities.
Future Projections: Future growth depends on clinical trial success and potential regulatory approvals. Analyst estimates vary widely based on trial outcomes.
Recent Initiatives: Recent initiatives focus on advancing clinical trials for ONA-XR and CTX-472 and exploring potential partnerships.
Summary
Context Therapeutics is a clinical-stage biopharmaceutical company with promising drug candidates, but faces significant risks associated with drug development and regulatory approval. Its strengths lie in its focused approach and novel therapies, but its financial resources are limited. Successful clinical trials are crucial for the company's future success and shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Context Therapeutics Inc. SEC filings
- Company press releases
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on publicly available information and may be subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Context Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-10-20 | Co-Founder, President, CEO & Director Mr. Martin A. Lehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | |
Full time employees 12 | |||
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.